On Monday, Shares of Wells Fargo & Company (NYSE:WFC), lost -0.19% to $56.98.
Wells Fargo Securities, the capital markets and investment banking business of Wells Fargo & Company (WFC), declared that Anish Lohokare has joined the firm as a director and senior research analyst in Structured Products Research.
“Anish brings noteworthyexpertise to his role with 11 years of agency RMBS and rates experience from the sell-side and both Fannie Mae and Freddie Mac,” said Diane Schumaker-Krieg, global head of Research, Economics & Strategy at Wells Fargo Securities.
Lohokare joined Wells Fargo Securities from BNP Paribas, where he was the lead RMBS strategist with a focus on both Agency RMBS and Interest Rates. His previous sell-side research experience comprises serving as Agency RMBS and Rates strategist for Deutsche Bank Securities.
Lohokare also worked at Fannie Mae and Freddie Mac, where his duties comprised of pricing credit and structuring CMOs. He holds a bachelor of technology in mechanical engineering from the Indian Institute of Technology and a master of science in administration science and engineering from Stanford University.
Wells Fargo & Company provides retail, commercial, and corporate banking services to individuals, businesses, and institutions. Its Community Banking segment offers checking, savings, market rate, individual retirement, and health savings accounts, in addition to time deposits and remittances; and lines of credit, auto floor plan lines, equity lines and loans, equipment and transportation loans, education and residential mortgage loans, and debit and credit cards.
Shares of Baxter International Inc. (NYSE:BAX), declined -0.47% to $67.94, during its last trading session.
Baxter International, issued its 16th annual Sustainability Report detailing the company’s progress creating social, environmental and economic value by addressing the needs of stakeholders worldwide.
Baxter’s 2014 Sustainability Report, accessible at baxter.com/sustainability-report, highlights recent actions taken by the company that align with its nine sustainability precedingities, which comprise strengthening access to healthcare, creating an inclusive workplace and enhancing math and science education. Priorities also comprise a range of environmental initiatives such as reducing greenhouse gas emissions, waste generation, and water use. Baxter’s Sustainability Report is aligned with the Global Reporting Initiative G3 Guidelines, which provide a uniform and transparent set of metrics to systematically report on sustainability initiatives and results.
”Baxter’s accomplishments and aspirations as a corporate citizen depend on our sustainability as a business,” said Robert L. Parkinson, Jr., Baxter’s chairman and chief executive officer. ”As a healthcare industry leader, we must constantly advance and innovate to create lasting social, environmental and economic value for the communities we serve worldwide.”
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products.
Finally, Galena Biopharma, Inc. (NASDAQ:GALE), ended its last trade with 5.29% surge, and closed at $1.99.
Galena Biopharma, declared that data from the Company’s Phase 2 clinical trial of GALE-401 was presented at the European Hematology Association 20th Congress in Vienna, Austria. The GALE-401 Phase 2 pilot study is a single arm, open label, multi-center study evaluating the efficacy and safety of anagrelide controlled release in subjects with thrombocytosis secondary to essential thrombocythemia (ET) and other myeloproliferative neoplasms (MPNs).
The poster presentation, entitled, “Phase 2 Study of a Novel Controlled-Release Formulation of Anagrelide (GALE-401) in Subjects with Myeloproliferative Neoplasm (MPN)-Related Thrombocytosis,” was presented on Saturday, June 13, 2015. The Phase 2 study demonstrated that GALE-401 was well tolerated with primarily Grade 1 and 2 toxicities in 16 of the 18 subjects enrolled. The efficacy shown in the trial compares favorably to historical anagrelide immediate release (IR) response rates with the following platelet response: overall response rate (ORR) of 78% (14/18); complete response (CR) of 39% (7/18); partial response (PR) of 39% (7/18). The median time to response was 5 weeks (range, 3-10), and the median duration of response has not yet been reached. Based on the data, the investigators concluded that GALE-401 remains a viable potential treatment option for MPNs, and a randomized trial comparing GALE-401 as compared to anagrelide IR is warranted. Final data from the GALE-401 Phase 2 trial is predictable to be presented at the American Society of Hematology conference in December.
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products comprise Abstral, a sublingual tablet that is used for the administration of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of emetogenic chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
